Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis.

ABSTRACT:

Background

Teriparatide (TPTD) is a widely used anabolic agent for the treatment of osteoporosis. Several factors have been identified to be related to bone mineral density (BMD) increase in anti-osteoporosis treatment with other agents; however, there has been no systematic analysis to summarize the associated determinants of BMD reaction to daily teriparatide treatment.

Methods

In this retrospective study, we performed a comprehensive investigation involving not only clinical data but also several relevant lifestyle factors to be examined for their potential contribution to BMD response. This post-hoc analysis included 258 post-menopaused patients with osteoporosis who received TPTD at 20 µg/day for 12 months. Univariate and multivariate analyses were conducted to distingu

SUBMITTER: Kong M 

PROVIDER: S-EPMC10837964 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature